Sumatriptan Other names: Sumatriptan succinate

Chemical formula: C₁₄H₂₁N₃O₂S  Molecular mass: 295.4 g/mol  PubChem compound: 5358

Therapeutic indications

Sumatriptan is indicated for:

Migraine attacks

Population group: only adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Sumatriptan is indicated for the acute relief of migraine attacks, with or without aura. Sumatriptan should only be used where there is a clear diagnosis of migraine.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Cluster headache

Population group: only adults (18 - 65 years old)

Cluster headache

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Sumatriptan is contraindicated in the following cases:

History of myocardial infarction, ischaemic heart disease, coronary vasospasm, peripheral vascular disease

at least one of
Past history of myocardial infarction
Ischemic heart disease
Coronary artery spasm
Peripheral vascular disease

Lactation

Lactation

History of cerebrovascular accident, history of transient ischaemic attack

at least one of
H/O: CVA
History of transient ischemic attack

Severe hepatic impairment

Hepatic failure stage IV

Ergotamine, ergotamine derivatives, triptans

at least one of
Ergotamine
Ergot alkaloids
Selective serotonin (5HT1) agonists

Monoamine oxidase inhibitors

Monoamine oxidase inhibitors (MAOIs)

Uncontrolled hypertension

Hypertension

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2021: IMIGRAN Nasal spray, solution
Structured Product Labeling (SPL/PLR) 2017: IMITREX Nasal spray
Summary of Product Characteristics (SPC) 2020: IMIGRAN Solution for injection
Structured Product Labeling (SPL/PLR) 2020: IMITREX Solution for injection
Structured Product Labeling (SPL/PLR) 2020: IMITREX Film-coated tablet
Summary of Product Characteristics (SPC) 2021: IMIGRAN Tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈